Cetera Investment Advisers Sells 4,227 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Cetera Investment Advisers has significantly reduced its stake in TransMedics Group by 51.2%, selling 4,227 shares and now holds 4,033 shares valued at approximately $271,000.
• Institutional investors own nearly 99.67% of TransMedics Group stock, with notable recent activity including Braidwell LP acquiring a substantial stake of around $57.5 million.
• TransMedics Group reported earnings of $0.92 per share, exceeding estimates, and showed a year-over-year revenue increase of 37.7%, with a current market cap of $4.15 billion.

Cetera Investment Advisers cut its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 51.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,033 shares of the company's stock after selling 4,227 shares during the period. Cetera Investment Advisers' holdings in TransMedics Group were worth $271,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in TransMedics Group in the first quarter worth approximately $25,000. Hager Investment Management Services LLC raised its position in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares during the period. CWM LLC lifted its holdings in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after purchasing an additional 155 shares in the last quarter. GAMMA Investing LLC grew its position in TransMedics Group by 551.7% in the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after purchasing an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. grew its position in TransMedics Group by 46.7% in the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after purchasing an additional 700 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Up 0.9%

TMDX stock traded up $1.04 during trading on Friday, reaching $119.85. The stock had a trading volume of 1,032,110 shares, compared to its average volume of 1,241,494. The company has a market capitalization of $4.09 billion, a price-to-earnings ratio of 62.10 and a beta of 2.09. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company's 50 day moving average is $121.65 and its two-hundred day moving average is $101.51. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's revenue was up 37.7% on a year-over-year basis. During the same period last year, the business posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director owned 2,866 shares of the company's stock, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Oppenheimer boosted their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Finally, Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.